Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | ACE | P12821 | 1/20 | 0.36 |
| ▸ | CYP24A1 | Q07973 | 1/20 | 0.36 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.36 |
| ▸ | CTSG | P08311 | 1/20 | 0.36 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.36 |
| ▸ | CMA1 | P23946 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15271471 | 1.00 | BLM (0.38) | BLMKMT2AALDH1A1CYP1A2CYP2C9 | |
| SCHEMBL16414800 | 1.00 | BLM (0.38) | BLMKMT2AALDH1A1CYP1A2CYP2C9 | |
| SCHEMBL6444947 | 0.85 | MMP13 (0.36) | BLMCYP24A1PRSS1CTSGCTRB1 | |
| SCHEMBL15184990 | 0.85 | MMP13 (0.36) | BLMCYP24A1PRSS1CTSGCTRB1 | |
| SCHEMBL12549853 | 0.84 | PRSS1 (0.33) | BLMCYP24A1PRSS1CTSGCTRB1 | |
| SCHEMBL7552725 | 0.83 | PRSS1 (0.34) | KMT2AALDH1A1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL17429760 | 0.83 | PRSS1 (0.32) | BLMCYP24A1PRSS1CTSGCTRB1 | |
| SCHEMBL7552716 | 0.83 | PRSS1 (0.34) | KMT2AALDH1A1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL4494128 | 0.83 | PRSS1 (0.34) | KMT2AALDH1A1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL4494121 | 0.83 | PRSS1 (0.34) | KMT2AALDH1A1CYP1A2CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150031898-A1 | PROCESS FOR PREPARATION OF PROSTAGLANDIN F2 ALPHA ANALOGUES | INSTYTUT FARMACEUTYCZNY (PL) | 2015-01-29 | — | — | US | claimed |
| US-20150031898-A1 | PROCESS FOR PREPARATION OF PROSTAGLANDIN F2 ALPHA ANALOGUES | INSTYTUT FARMACEUTYCZNY (PL) | 2015-01-29 | — | — | US | disclosed |
| EP-2822927-A1 | PROCESS FOR PREPARATION OF PROSTAGLANDIN F2alpha ANALOGUES | INSTYTUT FARMACEUTYCZNY (PL) | 2015-01-14 | — | — | EP | disclosed |
| WO-2013133730-A1 | PROCESS FOR PREPARATION OF PROSTAGLANDIN F2α ANALOGUES | INSTYTUT FARMACEUTYCZNY (PL) | 2013-09-12 | — | — | WO | disclosed |
| EP-0839798-B1 | Intermediates for preparating non-peptide retroviral protease inhibitors | ABBOTT LAB (US) | 2005-08-17 | — | — | EP | disclosed |
| EP-0402646-B1 | Retroviral protease inhibiting compounds | ABBOTT LAB (US) | 1998-07-22 | — | — | EP | disclosed |
| EP-0839798-A2 | Intermediates for preparating non-peptide retroviral protease inhibitors | ABBOTT LABORATORIES (US) | 1998-05-06 | — | — | EP | disclosed |
| US-5670675-A | Retroviral protease inhibiting compounds | ABBOTT LABORATORIES (US) | 1997-09-23 | — | — | US | disclosed |
| US-5545750-A | TREATING HUMAN IMMUNODEFICIENCY VIRUS | ABBOTT LABORATORIES (US) | 1996-08-13 | — | — | US | disclosed |
| US-5142056-A | Human immunodeficiency virus protease inhibitor | ABBOTT LABORATORIES (US) | 1992-08-25 | — | — | US | disclosed |
| EP-0402646-A1 | Retroviral protease inhibiting compounds | ABBOTT LABORATORIES (US) | 1990-12-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150031898-A1 | PROCESS FOR PREPARATION OF PROSTAGLANDIN F2 ALPHA ANALOGUES | PTGES, PTGIS, PTGES2 | BLM 2808/4885KMT2A 4092/4885ALDH1A1 968/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.